Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
60.14
-2.14 (-3.44%)
At close: Jun 5, 2026, 4:00 PM EDT
60.00
-0.14 (-0.23%)
After-hours: Jun 5, 2026, 6:40 PM EDT
Oruka Therapeutics Employees
Oruka Therapeutics had 68 employees as of December 31, 2025. The number of employees increased by 40 or 142.86% compared to the previous year.
Employees
68
Change (1Y)
40
Growth (1Y)
142.86%
Revenue / Employee
n/a
Profits / Employee
-$1,385,147
Market Cap
3.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 68 | 40 | 142.86% |
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Beam Therapeutics | 522 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 154 |
| Tango Therapeutics | 137 |
| Erasca | 103 |
ORKA News
- 2 days ago - Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Oruka Therapeutics Transcript: AGM 2026 - Transcripts
- 8 days ago - Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Oruka Therapeutics reports Q1 EPS (48c), consensus (54c) - TheFly
- 23 days ago - Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 23 days ago - Oruka Therapeutics Quarterly report: Q1 2026 - Filings
- 23 days ago - Oruka Therapeutics Earnings release: Q1 2026 - Filings
- 4 weeks ago - Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis - TheFly